Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPF-D
- Development stage
- Preclinical
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- Small Molecules
- Administration
- Enteral
01
Overview
TPF-D is an enteral nutrition emulsion developed by the Emergency Department of Affiliated Hospital of Xuzhou Medical College and Affiliated Hospital of Xuzhou Medical College. It is currently being investigated for its effects on blood glucose levels and prognosis in patients with stress hyperglycemia. Additionally, it is being studied for its effectiveness in patients with chronic wounds and diabetes. A related formulation, TPF-DM, is described as a high-fat, high-energy, low-carbohydrate enteral complete nutrition preparation, suitable for cancer patients, containing ω-3 fatty acids, vitamins A, C, E, and dietary fiber to support immune function, enhance resistance, and maintain gastrointestinal health.
- Brand names
- Ruidai
- Other names
- enteral nutrition emulsion (TPF-D)
Beyond the preview
Go deeper on TPF-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPF-D.